PD+ group | PD− group | p-value | |
---|---|---|---|
Cases, n | 27 | 206 | – |
Age at surgery (years) | 70.6 ± 6.3 | 72.5 ± 8.5 | 0.18 |
Sex (male/female, n) | 5/22 | 32/174 | 0.58 |
BMI | 22.8 ± 4.2 | 23.2 ± 3.7 | 0.59 |
BMD (T-score) | −1.900 ± 1.249 | − 1.863 ± 0.924 | 0.93 |
Medications for PD | |||
Dopamine precursors (yes/no) | 23/4 (85.2%) | – | – |
Dopamine agonists (yes/no) | 8/19 (29.6%) | – | – |
Monoamine oxidase type B inhibitors (yes/no) | 6/21 (22.2%) | – | – |
Other | 4/23 (14.8%) | – | – |
Medical comorbidities | |||
Diabetes (yes/no) | 1/26 (3.7%) | 22/184 (10.7%) | 0.49 |
Rheumatoid arthritis (yes/no) | 0/27 | 9/197 (4.4%) | 0.60 |
Renal dysfunction (yes/no) | 0/27 | 19/187 (9.2%) | 0.14 |
Cardiovascular disease (yes/no) | 2/25 (7.4%) | 26/180 (12.6%) | 0.75 |
Cerebrovascular disease (yes/no) | 5/22 (18.5%) | 14/192 (6.8%) | 0.053 |
Respiratory disease (yes/no) | 0/27 | 21/185 (10.2%) | 0.14 |
Follow-up duration (months) | 50.3 ± 16.2 | 49.0 ± 14.1 | 0.68 |
Number of fixed levels | 9.3 ± 2.6 | 7.8 ± 1.9 | 0.006 |
3CO (yes/no) | 17/10 | 100/106 | 0.14 |
Etiology (post fracture/degenerative/previous lumbar fusion) | 10/15/2 | 21/133/52 | 0.001 |
Fix to sacrum (yes/no) | 22/5 (81.5%) | 174/32 (84.1%) | 0.78 |
Pre SVA (mm) | 196.0 ± 63.7 | 135.4 ± 69.9 | < 0.001 |
Pre LL (°) | 2.1 ± 19.3 | 3.5 ± 20.5 | 0.75 |
Pre TLK (°) | 18.1 ± 16.0 | 19.2 ± 17.0 | 0.28 |
Pre TK (°) | 24.1 ± 15.4 | 27.4 ± 20.0 | 0.37 |
Pre SS (°) | 17.1 ± 8.0 | 14.7 ± 11.4 | 0.34 |
Pre PT (°) | 36.6 ± 8.6 | 34.5 ± 13.2 | 0.47 |
PI (°) | 53.6 ± 9.6 | 49.8 ± 9.1 | 0.088 |